Skip to NavigationSkip to content

brexit

FMD would not apply in case of no-deal Brexit

The Falsified Medicines Directive would be scrapped in the event of a no deal Brexit, the Association of the British Pharmaceutical Industry (ABPI) has warned. The scrapping of the EU legislation could put patients at risk.

Read Pharmafocus January/February 2019 edition online now!

We’re slowly edging towards warmer months, but the New Year brings more than just the promise of more amicable weather; in a manner reminiscent of past years, industry M&A is off to an explosive start, as multinational drug firm Bristol-Myers Squibb announced within the first days of the year that it had entered into an agreement to acquire Celgene for approximately $74 billion – the biggest pharma acquisition ever.

Novartis warns of huge impact of no-deal Brexit

Swiss pharmaceutical company Novartis has called on the British government to ‘ensure continuity of supply’ in the case of a ‘disorderly’ no-deal Brexit.

“It is vital that Government makes minimising disruption to the medicines supply the highest priority as it prepares for a potential hard or disorderly Brexit and ensures cooperation over medicines regulation in this event,” the company said.

Government unveils £20bn plan to revitalise NHS in England

Image Credit: Kuhlmann / MSC

Theresa May and the chief executive of NHS England, Simon Stevens, have announced a new ten year plan for the NHS. It is hoped that the long term plan, which is focused on prevention and early detection, may save up to 500,000 lives.

In essence the plan will give an additional £20 billion to the NHS in England by 2023/24. The additional £20 billion cash injection will be spread out over five years up until 2023/24 representing a 3.4% increase year on year. 

Top Ten most popular articles on Pharmafile.com of 2018!

Image Credit: patricia m https://www.flickr.com/photos/taffeta/38707779504/

Brexit, business and biosimilars, seemed to be the three themes of 2018. As Brexit negotiations reached a stalemate the pharmaceutical industry continued to innovate. The top story of the year covered the fact that Amgen’s biosimilar prove non-inferior to Johnson & Johnson’s Remicade in rheumatoid arthritis. Meanwhile the British parliament’s choice to remain within the EMA regulatory network took second place, followed closely behind by the launch of another high profile biosimilar.

Top Ten most popular articles on Pharmafile.com this week!

Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration worth billions. Meanwhile Japanese company Taisho revealed they were set to buy Bristol-Myers Squibb’s consumer healthcare business in a deal worth $1.6 billion. To top it off Swiss pharma giant Novartis signed a deal with Canadian cannabis company which propelled the latter’s stocks up by more than 11%.

No-deal Brexit stockpiling puts pressure on supply chain

The stockpiling of medicines in preparation for a no-deal Brexit is putting pressure on the supply chain and causing shortages of generic medicines, according to Simon Dukes, chief executive of the PSNC. The increased demand has in turn led to fluctuating prices, additional costs that will have to be picked up by the NHS.

Top Ten most popular articles on Pharmafile.com this week!

Takeda’s acquisition of Shire finally got the go-ahead this week as 88% of shareholders voted in favour of French CEO Christophe Weber’s plan which will propel the Japanese firm into 8th position among drugmakers worldwide.

Health Secretary Matt Hancock says government may charter flights to deliver medicines in case of no-deal Brexit

British health secretary Matt Hancock has said the government is working out ways through which they could charter flights in order to deliver medicines, as preparations are made for a potential ‘no-deal’ Brexit.

Talking to BBC Radio 4’s Today programme, when asked about chartering planes, Hancock said, “We are working on exactly how we are going to do that, but that is part of the work we are doing.”

83% in healthcare say UK will not be attractive for R&D and manufacturing post-Brexit

Image credit: GlobalData report, Brexit and the Healthcare Industry – Implications for Pharma, Q3 2018

As the Brexit crisis continues to spiral, new findings from GlobalData reveal that 83% of healthcare professionals in the UK believe that the country will no longer present an attractive destination for healthcare research and manufacturing after it leaves the European Union.

This figure has continued to rise. The report, titled Brexit and the Healthcare Industry – Implications for Pharma, Q3 2018, sought to gauge the evolving sentiment towards Brexit from the healthcare community.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches